Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jan 25, 2022
Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...
Read More...
Jan 20, 2022
Suneva Medical Inc. inked a merger agreement with Viveon Health On January 12, 2022, Suneva Medical Inc., a leading regenerative aesthetics company, and Viveon Health Acquisition Corp., a particular purpose acquisition company, entered into a definitive merger agreement to establish a new regenerative aesthetics...
Read More...
Jan 18, 2022
Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment. A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenp...
Read More...
Jan 11, 2022
Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with...
Read More...
Jan 06, 2022
Siemens Healthineers received Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test by the FDA On December 29, 2021, Siemens Healthineers was granted Emergency Use Authorization (EUA) for its CLINITEST Rapid COVID-19 Antigen Self-Test by the United States Food and Drug Administration ...
Read More...
Jan 04, 2022
FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 for treating metastatic castration-resistant prostate cancer (mCRPC). An i...
Read More...
Dec 30, 2021
Oracle Corporation sets to acquire Cerner Corporation On December 20, 2021, Oracle Corporation and Cerner Corporation entered into an agreement as per which Oracle will acquire Cerner through an all-cash tender offer for approximately USD 28.3 billion in equity value. Larry Ellison, Chairman and C...
Read More...
Dec 28, 2021
Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s app...
Read More...
Dec 23, 2021
Sky receives FDA clearance to market the geko™ device for venous insufficiency and ischemia On December 16, 2021, Sky Medical Technology Ltd, a medical device company, got approval from the US Food and Drug Administration (FDA) 510(k) to market the geko™ device for growing microcirculatory bl...
Read More...
Dec 16, 2021
First patient enrolled in BrainQ's Pivotal Trial, EMAGINE™, for frequency-tuned electromagnetic field therapy to reduce disability following Ischemic Stroke On December 09, 2021, BrainQ announced the enrollment of the first patient at MedStar National Rehabilitation Hospital in its pivotal, randomized, ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper